XANAP: A real‐world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia-Reference-Cited by-同舟云学术

XANAP: A real‐world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia

Published:2018-07-06 Issue:4 Volume:34 Page:418-427
ISSN:1880-4276
Container-title:Journal of Arrhythmia
language:en
Short-container-title:J Arrhythmia

Author:

Kim Young‐Hoon¹,Shim Jaemin¹,Tsai Chia‐Ti²,Wang Chun‐Chieh³,Vilela Gilbert⁴,Muengtaweepongsa Sombat⁵,Kurniawan Mohammad⁶,Maskon Oteh⁷,Li Fern Hsu⁸,Nguyen Thang Huy⁹,Thanachartwet Thititat¹⁰,Sim Kenneth¹⁰,Camm A. John¹¹,

Affiliation:

1. Korea University Medical Centre Seoul South Korea

2. National Taiwan University Hospital Taipei Taiwan

3. Chang Gung Memorial Hospital Chang Gung University Taoyuan Taiwan

4. Philippine Heart Center Quezon City Philippines

5. Faculty of Medicine Stroke Excellence Center Thammasat University Pathum Thani Thailand

6. Department of Neurology Faculty of Medicine Cipto Mangunkusumo National Hospital Universitas Indonesia Jakarta Indonesia

7. Department of Medicine National University of Malaysia Medical Centre (UKMMC) Kuala Lumpur Malaysia

8. Novena Heart Centre Mount Elizabeth Novena Specialist Centre Singapore City Singapore

9. Neurology Department Pham Ngoc Thach Medical University Ho Chi Minh City Vietnam

10. Bayer (South East Asia) Pte Ltd Singapore City Singapore

11. Cardiology Clinical Academic Group St. George's University of London and Imperial College London UK

Funder

Janssen Pharmaceuticals

Bayer

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/joa3.12073

Reference26 articles.

1. Asian strategy for stroke prevention in atrial fibrillation

2. Dabigatran versus Warfarin in Patients with Atrial Fibrillation

3. Apixaban versus Warfarin in Patients with Atrial Fibrillation

4. Oral anticoagulants for Asian patients with atrial fibrillation

5. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS;Europace;2024-06-29

2. Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry;Scientific Reports;2024-02-02

3. Efficacy and safety of rivaroxaban in prevention and therapy of thromboembolic events in patients with nonvalvular atrial fibrillation;Journal of the Practice of Cardiovascular Sciences;2023

4. Left atrial appendage closure in nonvalvular atrial fibrillation patients with percutaneous coronary intervention;BMC Cardiovascular Disorders;2022-10-03

5. Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation;Pharmaceutics;2022-08-21